Penumbra Inc (NYSE:PEN) Director Harpreet Grewal sold 237 shares of Penumbra stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $134.93, for a total transaction of $31,978.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Harpreet Grewal also recently made the following trade(s):
- On Tuesday, September 3rd, Harpreet Grewal sold 475 shares of Penumbra stock. The shares were sold at an average price of $144.81, for a total transaction of $68,784.75.
Shares of NYSE:PEN traded up $3.69 on Thursday, reaching $139.20. The company’s stock had a trading volume of 838,500 shares, compared to its average volume of 451,423. Penumbra Inc has a 52-week low of $110.84 and a 52-week high of $185.70. The company has a market cap of $4.68 billion, a P/E ratio of 272.94, a PEG ratio of 7.76 and a beta of 0.71. The company has a 50-day simple moving average of $142.33 and a 200 day simple moving average of $149.59. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.33 and a current ratio of 6.23.
Several large investors have recently modified their holdings of PEN. HM Payson & Co. purchased a new position in shares of Penumbra in the 2nd quarter worth $80,000. Machina Capital S.A.S. purchased a new position in shares of Penumbra during the 2nd quarter worth about $155,000. CENTRAL TRUST Co purchased a new position in shares of Penumbra during the 2nd quarter worth about $171,000. Ellington Management Group LLC purchased a new position in shares of Penumbra during the 2nd quarter worth about $208,000. Finally, Macquarie Group Ltd. purchased a new position in shares of Penumbra during the 2nd quarter worth about $240,000. 85.73% of the stock is owned by institutional investors and hedge funds.
A number of analysts have issued reports on PEN shares. Royal Bank of Canada set a $174.00 price target on shares of Penumbra and gave the company a “buy” rating in a report on Wednesday, August 7th. Zacks Investment Research downgraded shares of Penumbra from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Bank of America lifted their price objective on shares of Penumbra from $150.00 to $180.00 and gave the stock a “buy” rating in a research note on Thursday, June 13th. ValuEngine cut shares of Penumbra from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Wells Fargo & Co lifted their price objective on shares of Penumbra from $180.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Penumbra presently has a consensus rating of “Buy” and a consensus target price of $167.14.
Penumbra Company Profile
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Featured Article: What is Cost of Debt?
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.